Literature DB >> 19170834

The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response.

Lucia Alves da Silva Lara1, Bernardo Useche, Rui Alberto Ferriani, Rosana Maria Reis, Marcos Felipe Silva de Sá, Mauricio Mesquita Sabino de Freitas, Julio César Rosa e Silva, Ana Carolina Japur de Sá Rosa e Silva.   

Abstract

INTRODUCTION: The sexual response depends on the adequate function of all systems related to the genital and extra-genital organs. Physiological conditions such as menopause can interfere with sexual expression because of central and peripheral changes. Genital effects of estrogen include vaginal trophism, lubrication, and local pleasure sensation in the sexual arousal phase. Hypoestrogenism causes changes in the four layers of the vaginal wall that may result in dyspareunia and a loss in the quality of the genital arousal response. AIM: The purpose of this review is to highlight the changes in the vaginal wall caused by hypoestrogenism, its possible relationship with dyspareunia, and its repercussions for genital arousal. Treatments for hypoestrogenism are also discussed.
METHODS: We evaluated the data available in PubMed (1982-2008) and surveyed the reference list for relevant studies. Two reviewers analyzed the data independently. A study was considered to be of high quality if it had all three of the following characteristics: (i) prospective design; (ii) valid data; and (iii) adequate sample size. Reviews and experimental animal studies were also considered. MAIN OUTCOME MEASURES: Normal genital morphology, hypoestrogenism and hormone replacement therapy were the focus of the studies reviewed in this paper.
RESULTS: Atrophy of the vaginal wall may be associated with dyspareunia and genital sexual arousal disorder, but psychological and sociocultural aspects must also be considered. Regardless, however, local estrogen therapy is useful in improving vaginal wall trophism and, thus, in improving the sexual response.
CONCLUSIONS: There are many possible alterations in the structure of the vaginal wall that are related to estrogen deficiency that may require medical intervention beyond the usual strategies used to attain adequate sexual function. Physicians should attempt to treat these alterations, and more research is needed to elucidate the physiopathology of dyspareunia and genital sexual arousal physiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19170834     DOI: 10.1111/j.1743-6109.2008.01052.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  12 in total

1.  Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women.

Authors:  Tomas L Griebling; Zhaohui Liao; Peter G Smith
Journal:  Menopause       Date:  2012-06       Impact factor: 2.953

2.  Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Authors:  Debra L Barton; Jeff A Sloan; Lynne T Shuster; Paula Gill; Patricia Griffin; Kathleen Flynn; Shelby A Terstriep; Fauzia N Rana; Travis Dockter; Pamela J Atherton; Michaela Tsai; Keren Sturtz; Jacqueline M Lafky; Mike Riepl; Jacqueline Thielen; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-09-18       Impact factor: 3.603

3.  Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).

Authors:  Debra L Barton; Lynne T Shuster; Travis Dockter; Pamela J Atherton; Jacqueline Thielen; Stephen N Birrell; Richa Sood; Patricia Griffin; Shelby A Terstriep; Bassam Mattar; Jacqueline M Lafky; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-11-21       Impact factor: 3.603

4.  Cryopreservation time does not decrease follicular viability in ovarian tissue frozen for fertility preservation.

Authors:  Jacira Ribeiro Campos; Julio Cesar Rosa-e-Silva; Bruno Ramalho Carvalho; Alessandra Aparecida Vireque; Marcos Felipe Silva-de-Sá; Ana Carolina Japur de Sá Rosa-e-Silva
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Anatomic distribution of nerves and microvascular density in the human anterior vaginal wall: prospective study.

Authors:  Ting Li; Qinping Liao; Hong Zhang; Xuelian Gao; Xueying Li; Miao Zhang
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

Review 6.  Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Clin Interv Aging       Date:  2014-11-13       Impact factor: 4.458

7.  Lubricant use during intercourse and time to pregnancy: a prospective cohort study.

Authors:  K A McInerney; K A Hahn; E E Hatch; E M Mikkelsen; A Z Steiner; K J Rothman; H T Sørensen; T M Snerum; L A Wise
Journal:  BJOG       Date:  2018-04-15       Impact factor: 6.531

8.  Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy.

Authors:  Lisa A Chism
Journal:  Int J Womens Health       Date:  2012-10-12

9.  Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy.

Authors:  Mary Jane Minkin; Ricardo Maamari; Suzanne Reiter
Journal:  Int J Womens Health       Date:  2013-03-15

Review 10.  Female reproductive tract pain: targets, challenges, and outcomes.

Authors:  Phillip Jobling; Kate O'Hara; Susan Hua
Journal:  Front Pharmacol       Date:  2014-02-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.